Sensei Biotherapeutics Company Insiders
| SNSE Stock | USD 9.09 0.25 2.83% |
Sensei Biotherapeutics' insiders are aggressively selling. The analysis of the overall insider sentiment regarding Sensei Biotherapeutics suggests that all insiders are panicking. Sensei Biotherapeutics employs about 14 people. The company is managed by 13 executives with a total tenure of roughly 33 years, averaging almost 2.0 years of service per executive, having 1.08 employees per reported executive.
Insider Sentiment 0
Mostly Selling
Selling | Buying |
Latest Trades
| 2025-12-09 | James Peyer | Disposed 3507 @ 7.96 | View | ||
| 2025-12-08 | James Peyer | Disposed 3105 @ 8.59 | View | ||
| 2025-12-05 | James Peyer | Disposed 16295 @ 11.5 | View | ||
| 2025-12-04 | James Peyer | Disposed 5000 @ 9.06 | View |
Monitoring Sensei Biotherapeutics' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sensei Biotherapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in producer price index. Sensei Biotherapeutics' Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Sensei Biotherapeutics' future performance. Based on our forecasts, it is anticipated that Sensei will maintain a workforce of about 30 employees by March 2026.Sensei Biotherapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (0.3704) % which means that it has lost $0.3704 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7018) %, meaning that it created substantial loss on money invested by shareholders. Sensei Biotherapeutics' management efficiency ratios could be used to measure how well Sensei Biotherapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of February 15, 2026, Return On Tangible Assets is expected to decline to -0.63. The current year's Return On Capital Employed is expected to grow to -0.87. At present, Sensei Biotherapeutics' Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 4.3 M, whereas Other Assets are forecasted to decline to 1.09.As of February 15, 2026, Common Stock Shares Outstanding is expected to decline to about 27 M. In addition to that, Net Loss is expected to decline to about (45.9 M)The market capitalization of Sensei Biotherapeutics is $11.47 Million. Sensei Biotherapeutics maintains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Note, that even with negative profits, if the true value of the company is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Some institutional investors establish a significant position in stocks such as Sensei Biotherapeutics in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Sensei Biotherapeutics, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.
Sensei Biotherapeutics Workforce Comparison
Sensei Biotherapeutics is rated fourth in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 259. Sensei Biotherapeutics holds roughly 14.0 in number of employees claiming about 5% of equities under Health Care industry.
Sensei Biotherapeutics Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Sensei Biotherapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Sensei Biotherapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Sensei Biotherapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2025-12-01 | 0.1111 | 2 | 18 | 790.00 | 56,604 |
| 2025-03-01 | 2.0 | 4 | 2 | 640,000 | 7,834 |
| 2024-03-01 | 2.0 | 6 | 3 | 915,119 | 12,361 |
| 2023-09-01 | 9.5 | 19 | 2 | 171,644 | 3,174,604 |
| 2023-03-01 | 5.75 | 23 | 4 | 934,569 | 50,343 |
| 2021-09-01 | 0.25 | 1 | 4 | 16,667 | 95,822 |
| 2021-03-01 | 1.8667 | 56 | 30 | 10,458,790 | 781,254,604 |
Sensei Biotherapeutics Notable Stakeholders
A Sensei Biotherapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Sensei Biotherapeutics often face trade-offs trying to please all of them. Sensei Biotherapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Sensei Biotherapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| John MBA | CEO President | Profile | |
| Christopher JD | General President | Profile | |
| Edward Horst | Chief Officer | Profile | |
| Elisabeth Colunio | VP HR | Profile | |
| Lora Pike | Vice Communications | Profile | |
| Steven Fuller | Chief Officer | Profile | |
| Robert MD | Chief Officer | Profile | |
| Erin Colgan | Chief Officer | Profile | |
| MS MBA | Chief Officer | Profile | |
| Josiah Craver | Principal Finance | Profile | |
| MPH MBA | Chief Officer | Profile | |
| MBA MBA | CEO Pres | Profile | |
| FACP MD | Chief Officer | Profile |
About Sensei Biotherapeutics Management Performance
The success or failure of an entity such as Sensei Biotherapeutics often depends on how effective the management is. Sensei Biotherapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Sensei management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Sensei management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.60) | (0.63) | |
| Return On Capital Employed | (0.91) | (0.87) | |
| Return On Assets | (0.60) | (0.63) | |
| Return On Equity | (0.90) | (0.86) |
Please note, the presentation of Sensei Biotherapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Sensei Biotherapeutics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Sensei Biotherapeutics' management manipulating its earnings.
Sensei Biotherapeutics Workforce Analysis
Traditionally, organizations such as Sensei Biotherapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Sensei Biotherapeutics within its industry.Sensei Biotherapeutics Manpower Efficiency
Return on Sensei Biotherapeutics Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 2.2M | |
| Net Loss Per Executive | 2.3M | |
| Working Capital Per Employee | 2.6M | |
| Working Capital Per Executive | 2.8M |
Complementary Tools for Sensei Stock analysis
When running Sensei Biotherapeutics' price analysis, check to measure Sensei Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sensei Biotherapeutics is operating at the current time. Most of Sensei Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Sensei Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sensei Biotherapeutics' price. Additionally, you may evaluate how the addition of Sensei Biotherapeutics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| CEOs Directory Screen CEOs from public companies around the world |